Wall Street Zen Downgrades BioLife Solutions (NASDAQ:BLFS) to Hold

BioLife Solutions (NASDAQ:BLFS) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other equities analysts have also issued reports on BLFS. HC Wainwright lowered shares of BioLife Solutions from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $32.00 to $31.00 in a research report on Thursday. Jefferies Financial Group downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and increased their price target for the company from $30.00 to $31.00 in a report on Thursday. TD Cowen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and decreased their price target for the stock from $33.00 to $31.00 in a research report on Wednesday. William Blair set a $31.00 price objective on shares of BioLife Solutions in a report on Thursday. Finally, Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $31.43.

BioLife Solutions Price Performance

BLFS opened at $29.98 on Friday. The firm has a market capitalization of $1.46 billion, a P/E ratio of -374.70 and a beta of 1.94. The stock’s 50 day moving average price is $26.94 and its two-hundred day moving average price is $23.53. BioLife Solutions has a 12-month low of $17.86 and a 12-month high of $32.23.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.The company had revenue of $27.50 million for the quarter, compared to the consensus estimate of $25.66 million. As a group, analysts anticipate that BioLife Solutions will post 0.03 earnings per share for the current year.

Insider Activity

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the sale, the insider directly owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. The trade was a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 1,200,000 shares of company stock worth $28,125,000 in the last quarter. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its stake in shares of BioLife Solutions by 36.6% in the 2nd quarter. GAMMA Investing LLC now owns 8,996 shares of the medical equipment provider’s stock valued at $254,000 after buying an additional 2,410 shares in the last quarter. Bank of America Corp DE grew its stake in shares of BioLife Solutions by 73.4% in the 1st quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider’s stock valued at $17,250,000 after purchasing an additional 382,776 shares during the period. Royal Bank of Canada raised its holdings in shares of BioLife Solutions by 8.1% in the 1st quarter. Royal Bank of Canada now owns 885,298 shares of the medical equipment provider’s stock worth $16,891,000 after buying an additional 66,010 shares in the last quarter. Granahan Investment Management LLC raised its holdings in shares of BioLife Solutions by 49.7% in the 1st quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock worth $13,777,000 after buying an additional 239,701 shares in the last quarter. Finally, Cannell & Spears LLC raised its holdings in shares of BioLife Solutions by 3.2% in the 1st quarter. Cannell & Spears LLC now owns 26,261 shares of the medical equipment provider’s stock worth $493,000 after buying an additional 825 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions News Roundup

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.